Pivotal Therapeutics (PVTTF) 0.0765 $PVTTF
Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations
PR Newswire - Wed Jun 11, 9:34AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSEVO), ("Pivotal" or the "Company"
, a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.
Pivotal Therapeutics Announces First Quarter Financial Results
CNW Group - Fri May 30, 3:38PM CDT
Pivotal Therapeutics Inc. (OTCQXVTTF) (CSEVO), ("Pivotal" or the "Company", a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics announces changes to the Board of Directors
PR Newswire - Wed May 14, 6:28PM CDT
Pivotal Therapeutics Inc. (OTCQXVTTF)(CSEVO) ("Pivotal" or "the Company", a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, today announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development.
Pivotal Therapeutics grants incentive stock options
PR Newswire - Fri Mar 14, 4:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN(R) Commercialization
PR Newswire Europe - Tue Mar 04, 8:44AM CST
WOODBRIDGE, Ontario, March 4, 2014 /PRNewswire/ --
Pivotal Therapeutics closes financing; receives over CDN $7.7 million to further VASCAZEN® commercialization
CNW Group - Tue Mar 04, 7:00AM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580. Pivotal experienced greater demand than anticipated for the Financing and as a result was oversubscribed by 2,744 units resulting in an increase of $2,743,580 over the CDN $5,000,000 previously announced. The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co.
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA
HA Formulation
PR Newswire Europe - Wed Jan 29, 12:08PM CST
WOODBRIDGE, Ontario, January 29, 2014 /PRNewswire/ --
IIROC Trade Resumption - PVO
CNW Group - Wed Jan 29, 11:04AM CST
Trading resumes in:
IIROC Trading Halt - PVO (all issues)
CNW Group - Wed Jan 29, 10:45AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics announces second quarter 2013 financial results and corporate update
CNW Group - Wed Aug 28, 4:46PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its second quarter financial results for the three and six months ended June 30, 2013.
Pivotal Therapeutics Announces First Quarter 2013 Financial Results
CNW Group - Wed May 29, 11:34AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its financial results and operational highlights for the three months ended March 31, 2013. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations
PR Newswire - Wed Jun 11, 9:34AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSEVO), ("Pivotal" or the "Company", a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services. Pivotal Therapeutics Announces First Quarter Financial Results
CNW Group - Fri May 30, 3:38PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF) (CSEVO), ("Pivotal" or the "Company", a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated. Pivotal Therapeutics announces changes to the Board of Directors
PR Newswire - Wed May 14, 6:28PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF)(CSEVO) ("Pivotal" or "the Company", a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, today announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development. Pivotal Therapeutics grants incentive stock options
PR Newswire - Fri Mar 14, 4:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN(R) Commercialization
PR Newswire Europe - Tue Mar 04, 8:44AM CST
WOODBRIDGE, Ontario, March 4, 2014 /PRNewswire/ --
Pivotal Therapeutics closes financing; receives over CDN $7.7 million to further VASCAZEN® commercialization
CNW Group - Tue Mar 04, 7:00AM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580. Pivotal experienced greater demand than anticipated for the Financing and as a result was oversubscribed by 2,744 units resulting in an increase of $2,743,580 over the CDN $5,000,000 previously announced. The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co.
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA
HA Formulation PR Newswire Europe - Wed Jan 29, 12:08PM CST
WOODBRIDGE, Ontario, January 29, 2014 /PRNewswire/ --
IIROC Trade Resumption - PVO
CNW Group - Wed Jan 29, 11:04AM CST
Trading resumes in:
IIROC Trading Halt - PVO (all issues)
CNW Group - Wed Jan 29, 10:45AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics announces second quarter 2013 financial results and corporate update
CNW Group - Wed Aug 28, 4:46PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its second quarter financial results for the three and six months ended June 30, 2013.
Pivotal Therapeutics Announces First Quarter 2013 Financial Results
CNW Group - Wed May 29, 11:34AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its financial results and operational highlights for the three months ended March 31, 2013. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
